ePrints

Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus

Lookup NU author(s): Professor Jeffrey Pearson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Pepsin, acid and Helicobacter pylori are major factors in the pathophysiology of peptic ulcer disease and reflux oesophagitis. Ecabet sodium reduces the survival of H. pylori in the stomach and inhibits pepsin activity in the gastric juice of experimental animals. Here we have investigated the effects of ecabet sodium on some of the factors involved in the dynamics of the mucosal barrier, i.e. pepsins and mucins. This study used gastric juice obtained from 12 nonsymptomatic volunteers and nine patients with reflux oesophagitis. Ecabet sodium significantly inhibited pepsin activity in human gastric juice, with a maximum inhibition of 78%. Pepsin I, the ulcer-associated pepsin, was inhibited to the greatest extent. The ability of gastric juice to digest mucin was significantly inhibited by ecabet. As with gastric juice proteolytic activity, the inhibitory effect of ecabet on mucolysis was greater in gastric juice from patients with reflux oesophagitis than in that from controls. Ecabet sodium showed a positive interaction with gastric mucin, as assessed by an increase in viscosity. Thus ecabet sodium may reduce the aggressive potential of gastric juice towards the mucosa, which may be relevant in the treatment of reflux oesophagitis and peptic ulcer disease. In addition, it may strengthen the mucus barrier in peptic ulcer disease and gastritis.

Publication metadata

Author(s): Pearson JP; Roberts NB

Publication type: Article

Publication status: Published

Journal: Clinical Science

Year: 2001

Volume: 100

Issue: 4

Pages: 411-417

ISSN (print): 0143-5221

ISSN (electronic): 1470-8736

Publisher: Portland Press Ltd.

URL: http://dx.doi.org/10.1042/CS20000218

DOI: 10.1042/CS20000218

Altmetrics

Share